https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-s-shown-to-improve-survivalContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-s-shown-to-improve-survivalhttps://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-s-shown-to-improve-survival#u51216Sat, 29 Aug 2026 02:25:34 +0000The FDA approved Rasonque (daraxonrasib), a daily oral RAS inhibitor, for adults with advanced pancreatic cancer. Developed by RevMed, the medication blocks a protein that drives tumor growth. Clinical data indicates the drug can nearly double patient survival rates for one of the deadliest cancer forms. Patients including former UF President Sasse and a stage 4 patient in Maine have credited the pill with extending their lives.Why it mattersMetastatic pancreatic cancer has historically offered patients limited treatment options and short survival windows. This approval introduces the first pi https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-s-shown-to-improve-survivalhttps://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-s-shown-to-improve-survival#u50841Fri, 28 Aug 2026 11:01:25 +0000The FDA approved RASONQUE (daraxonrasib) on Wednesday to treat advanced pancreatic cancer. The once-daily pill blocks a protein that drives tumor growth and has shown the ability to nearly double patient survival rates. The drug is developed by RevMed and targets one of the deadliest forms of cancer. Early reports include a patient in Maine with stage 4 cancer and former UF President Sasse, who both credit the medication with extending their lives.Why it mattersPancreatic cancer is notoriously difficult to treat and often has low survival rates. This approval introduces a targeted approach to https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-s-shown-to-improve-survivalhttps://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-s-shown-to-improve-survival#u50091Thu, 27 Aug 2026 12:55:34 +0000The FDA has approved daraxonrasib, a once-daily pill designed to treat pancreatic cancer. The drug works by blocking a protein that drives tumor growth in most cases. Clinical data indicates the treatment nearly doubles patient survival rates. This approval introduces a new approach to managing a deadly disease, with some patients, including one with stage 4 cancer in Maine, reporting that the medication is extending their lives.Why it mattersPancreatic cancer is known as a deadly disease with historically limited treatment options. This drug targets a specific protein fueling tumors in the va